Sacubitril/valsartan in real-life clinical practice
Yıl: 2021 Cilt: 49 Sayı: 5 Sayfa Aralığı: 353 - 356 Metin Dili: İngilizce DOI: 10.5543/tkda.2021.21145 İndeks Tarihi: 29-01-2022
Sacubitril/valsartan in real-life clinical practice
Öz: -
Anahtar Kelime: Gerçek yaşamdaki klinik uygulamada sacubitril/valsartan
Öz: -
Anahtar Kelime: Belge Türü: Makale Makale Türü: Editoryal Erişim Türü: Erişime Açık
- 1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Crossref]
- 2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891-975.
- 3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Colvin MM, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: a Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016;68:1476-88. [Crossref]
- 4. Çavuşoğlu Y, Altay H, Ekmekçi A, Eren M, Küçükoğlu MS, Nalbantgil S, et al. Practical approaches for the treatment of chronic heart failure: frequently asked questions, overlooked points and controversial issues in current clinical practice. Anatol J Cardiol 2016;15:1-65. [Crossref]
- 5. Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21:998-1007. [Crossref]
- 6. Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-48. [Crossref]
- 7. Januzzi JL, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of change in N-terminal proB-type natriuretic peptide following ınitiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 2019;322:1085-95. [Crossref]
- 8. Desai AS, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, et al. Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction. JAMA 2019;322:1077-84. [Crossref]
- 9. Jering KS, Claggett B, Pfeffer MA, Granger C, Køber L, Lewis EF, et al. Prospective ARNI vs ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline chracteristics. Eur J Heart Fail 2021; doi: 10.1002/ejhf.2191. Online ahead of print. [Crossref]
- 10. Maddox TM, Januzzi JL, Allen LA, Breathett K, Butler J, Davis LL, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology solution set oversight committee. J Am Coll Cardiol 2021;77:772-810. [Crossref]
- 11. Çavuşoğlu Y, Altay H, Cahn A, Celik A, Demir S, Kılıçaslan B, et al. Sodium glucose co-transporter 2 inhibitors in heart failure therapy. Turk Kardiyol Dern Ars 2020;48:330-54. [Crossref]
- 12. Fu M, Vedin O, Svennblad B, Lampa E, Johansson D, Dahlström U, et al. Implementation of sacubitril/valsartan in Sweden: clinical chracteristics, titration patterns, and determinants. ESC Heart Fail 2020;7:3633-43. [Crossref]
- 13. Wachter R, Klebs S, Balas B, Kap E, Engelhard J, Schlienger R, et al. Heart failure signs and symptoms, hospital referrals, and prescription patterns in patients receivings sacubitril/valsartan in primary care and cardiologist setting in Germany. ESC Heart Fail 2020;7:2318-30. [Crossref]
- 14. Wachter R, Fonseca AF, Balas B, Kap E, Engelhard J, Schlienge R, et al. Real-world treatment patterns of sacubitril/valsartan: a longitudinal cohort study in Germany. Eur J Heart Fail 2019;21:588-97. [Crossref]
- 15. Thomas M, Khariton Y, Fonarow GC, Arnold SV, Hill L, Nassif ME, et al. Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure and reduced ejection fraction. ESC Heart Failure 2021; doi: 10.1002/ehf2.13298. Online ahead of print. [Crossref] Sacubitril/valsartan in real-life clinical practice 355
- 16. Ekici B, Yaman M, Küçük M, Dereli S, Yenerçağ M, Yiğit Z, et al. Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: real-world experience from Turkey (ARNi-TR). Turk Kardiyol Dern Ars 2021;49:357-67.
- 17. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril/valsartan vs enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM HF trial. Eur J Heart Fail 2016;18:1228-34. [Crossref]
- 18. Zile MR, Claggett B, Prescott MF, McMurray JJV, Packer M, Rouleau JL, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 2016;68: 2425-36. [Crossref]
- 19. Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM HF trial. Eur J Heart Fail 2019;21:337-41. [Crossref]
- 20. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glyceamic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM HF trial. Lancet Diabetes Endocrinol 2017;5:333-40. [Crossref]
| APA | Çavuşoğlu Y (2021). Sacubitril/valsartan in real-life clinical practice. , 353 - 356. 10.5543/tkda.2021.21145 |
| Chicago | Çavuşoğlu Yüksel Sacubitril/valsartan in real-life clinical practice. (2021): 353 - 356. 10.5543/tkda.2021.21145 |
| MLA | Çavuşoğlu Yüksel Sacubitril/valsartan in real-life clinical practice. , 2021, ss.353 - 356. 10.5543/tkda.2021.21145 |
| AMA | Çavuşoğlu Y Sacubitril/valsartan in real-life clinical practice. . 2021; 353 - 356. 10.5543/tkda.2021.21145 |
| Vancouver | Çavuşoğlu Y Sacubitril/valsartan in real-life clinical practice. . 2021; 353 - 356. 10.5543/tkda.2021.21145 |
| IEEE | Çavuşoğlu Y "Sacubitril/valsartan in real-life clinical practice." , ss.353 - 356, 2021. 10.5543/tkda.2021.21145 |
| ISNAD | Çavuşoğlu, Yüksel. "Sacubitril/valsartan in real-life clinical practice". (2021), 353-356. https://doi.org/10.5543/tkda.2021.21145 |
| APA | Çavuşoğlu Y (2021). Sacubitril/valsartan in real-life clinical practice. Türk Kardiyoloji Derneği Arşivi, 49(5), 353 - 356. 10.5543/tkda.2021.21145 |
| Chicago | Çavuşoğlu Yüksel Sacubitril/valsartan in real-life clinical practice. Türk Kardiyoloji Derneği Arşivi 49, no.5 (2021): 353 - 356. 10.5543/tkda.2021.21145 |
| MLA | Çavuşoğlu Yüksel Sacubitril/valsartan in real-life clinical practice. Türk Kardiyoloji Derneği Arşivi, vol.49, no.5, 2021, ss.353 - 356. 10.5543/tkda.2021.21145 |
| AMA | Çavuşoğlu Y Sacubitril/valsartan in real-life clinical practice. Türk Kardiyoloji Derneği Arşivi. 2021; 49(5): 353 - 356. 10.5543/tkda.2021.21145 |
| Vancouver | Çavuşoğlu Y Sacubitril/valsartan in real-life clinical practice. Türk Kardiyoloji Derneği Arşivi. 2021; 49(5): 353 - 356. 10.5543/tkda.2021.21145 |
| IEEE | Çavuşoğlu Y "Sacubitril/valsartan in real-life clinical practice." Türk Kardiyoloji Derneği Arşivi, 49, ss.353 - 356, 2021. 10.5543/tkda.2021.21145 |
| ISNAD | Çavuşoğlu, Yüksel. "Sacubitril/valsartan in real-life clinical practice". Türk Kardiyoloji Derneği Arşivi 49/5 (2021), 353-356. https://doi.org/10.5543/tkda.2021.21145 |
